Biological
Intramuscular vaccine
Intramuscular vaccine is a biological therapy with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
1(33%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
1
33%
Ph phase_2
1
33%
Ph phase_4
1
33%
Phase Distribution
1
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(2)
Detailed Status
Completed2
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 11 (33.3%)
Phase 21 (33.3%)
Phase 41 (33.3%)
Trials by Status
completed267%
active_not_recruiting133%
Recent Activity
1 active trials
Showing 3 of 3
completedphase_4
Immunogenicity of Influenza Vaccines in HIV-infected Persons in Thailand
NCT01538940
completedphase_1
Safety, Tolerability and Immunogenicinity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 Years.
NCT04450004
active_not_recruitingphase_2
Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults
NCT04636697
Clinical Trials (3)
Showing 3 of 3 trials
NCT01538940Phase 4
Immunogenicity of Influenza Vaccines in HIV-infected Persons in Thailand
NCT04450004Phase 1
Safety, Tolerability and Immunogenicinity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 Years.
NCT04636697Phase 2
Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults
All 3 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 3